Haleon plc (HLN) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $9.10, but acceptable to hold if already in. Reason: Below 200-day MA.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such... Read more
Hold if already holding. Not a fresh buy at $9.10, but acceptable to hold if already in. Reason: Below 200-day MA. Chart setup: Death cross but MACD improving, RSI 48. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-09Recent Developments — Haleon plc
Latest news
- NEWS Haleon to Invest £175M in New India Oral Health Plant — benzinga Jun 8, 2026 positive
- NEWS Haleon Voluntarily Recalls Four Lots Of Gas-X Extra Strength Softgels 125mg, 120 Ct. And 72 Ct. Distributed On Or About — benzinga Jun 4, 2026 negative
- NEWS Haleon's Centrum Announces Launch Of Centrum Adults 50+ Complete Multivitamin, Reformulated To Support Changing Nutritio — benzinga May 4, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $9.10, but acceptable to hold if already in. Reason: Below 200-day MA. Chart setup: Death cross but MACD improving, RSI 48. Maintain position. Not compelling to add more. Target $10.21 (+12.2%), stop $8.78 (−3.6%), A.R:R 2.3:1. Score 5.7/10, moderate confidence.
Take-profit target: $10.21 (+12.0% upside). Target $10.21 (+12.2%), stop $8.78 (−3.6%), A.R:R 2.3:1. Stop-loss: $8.78.
Below 200-day MA.
Haleon plc trades at a P/E of 18.1 (forward 14.6). TrendMatrix value score: 5.6/10. Verdict: Hold.
26 analysts cover HLN with a consensus score of 4.0/5. Average price target: $12.
What does Haleon plc do?Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various...
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.